News and Announcements
Proteomics International Raises $1.44 Placement and Now Offering a Share Purchase Plan
- Published January 10, 2017 11:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2nd December 2016, ASX Announcement
- Proteomics International is a specialist innovation-driven medical technology company based in Perth, Western Australia.
- Focused on the area of proteomics- the industrial scale study of the structure and functions of proteins.
- Established in 2001, providing services to groups throughout the Indo-Asian region. They consider themselves and are recognised as global leaders in their field of work.
Medtech company, Proteomics International Laboratories Ltd (PILL), is pleased to announce it has finalised the first phase of a targeted capital raising by placement of 6m shares at $0.24 to raise $1.44m. The oversubscribed “Placement” raised $1.44 million with the support from existing and new sophisticated investors.
The Placement received strong support overall from existing and new sophisticated investors and was significantly over-subscribed. The Placement was priced at $0.24 per share, with a discount of 12.7% to the last sale price. Proteomics also announced a Share Purchase Plan (SPP) to existing shareholders to raise $480, 000 at $0.24 per share. With K S Capital Pty Ltd acting as a Lead Manager to the Placement.
PILL recently announced important developments in both its areas of operation, Diagnostics and Analytical Services. The Board considered that these activities could be enhanced by an injection of capital.
The funds will therefore be used to contribute support to:
- The commercialisation and product development of PILLS’s flagship diagnostic product, PromarkerD, a breakthrough predictive test for diabetic kidney disease; and
- The roll-out of PILL’s new analytical testing services, in conjunction with Linear Clinical Research, for the fast-growing clinical trials market.
From the Placement, $500,000 has been allocated to each area, with the balance for working capital. Funds raised under the SPP will be distributed equally between the areas of diagnostics, analytical services and working capital. By fast-tracking its programs PILL seeks to bring forward its potential commercialisation deals for PromarkerD, and to expand sales from analytical services. Both areas continue to push the company towards cash-flow and positive operations.
To read the full announcement, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
